Regeneron Pharmaceuticals Inc. buy Maxi_Scalibusa
Summary
This prediction ended on 24.05.19 with a price of €282.73. The price of Regeneron Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -21.11%. Maxi_Scalibusa has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.250% | 0.250% | -0.741% | -11.366% |
| iShares Core DAX® | -0.559% | 0.738% | 14.807% | 57.558% |
| iShares Nasdaq 100 | -0.566% | -0.324% | 3.991% | 86.023% |
| iShares Nikkei 225® | 1.073% | 5.624% | 19.546% | 49.340% |
| iShares S&P 500 | 0.868% | 0.030% | 1.475% | 58.072% |
Comments by Maxi_Scalibusa for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharma


